Grant: Master's Award: Canada Graduate Scholarships
University of Ottawa
$17,500.00
Characterizing Oncolytically Advantageous Modifications in Vaccinia Virus
FY 2017-18
Summary
Despite our increasing understanding of cancer biology, cancer remains the leading cause of mortality in Canada, responsible for over 80 000 deaths annually. However, the toxicity of existing chemotherapies, coupled with their failure to account for the cellular complexity of tumours, highlights the demand for novel therapeutics. The field of oncolytic virotherapy, which uses uniquely engineered oncolytic viruses (OV) to specifically infect and kill cancer cells without harming healthy tissue, provides an innovative approach to cancer treatment. The OV-mediated cancer cell death generates a series of events which stimulate an anti-tumour immune response by the host, leading to efficient tumour control and eradication. In this study, I will be using Vaccinia virus (VacV) as my model virus. Otherwise known as the smallpox vaccine, VacV possesses an established safety profile, making it desirable for use as an OV. Recent work conducted in the Bell Lab has identified previously uncharacterized vaccinia genes which can be modified to enhance the cancer-killing and tumour spreading abilities of the virus. My role in this project will be to integrate and characterize a variety of these genomic manipulations into a VacV clone, and select for those presenting with enhanced oncolytic properties. This work will provide a better understanding of the OV interaction with the tumour microenvironment, bringing us closer towards the development of a novel oncolytic vaccinia candidate.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
386667
Name
Duong Jessie
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterizing Oncolytically Advantageous Modifications in Vaccinia Virus
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
A47l; Cancer Biology; Oncolytic Virotherapy; Vaccinia Virus; Virology; Virus Genetics
Abstract
Despite our increasing understanding of cancer biology, cancer remains the leading cause of mortality in Canada, responsible for over 80 000 deaths annually. However, the toxicity of existing chemotherapies, coupled with their failure to account for the cellular complexity of tumours, highlights the demand for novel therapeutics. The field of oncolytic virotherapy, which uses uniquely engineered oncolytic viruses (OV) to specifically infect and kill cancer cells without harming healthy tissue, provides an innovative approach to cancer treatment. The OV-mediated cancer cell death generates a series of events which stimulate an anti-tumour immune response by the host, leading to efficient tumour control and eradication. In this study, I will be using Vaccinia virus (VacV) as my model virus. Otherwise known as the smallpox vaccine, VacV possesses an established safety profile, making it desirable for use as an OV. Recent work conducted in the Bell Lab has identified previously uncharacterized vaccinia genes which can be modified to enhance the cancer-killing and tumour spreading abilities of the virus. My role in this project will be to integrate and characterize a variety of these genomic manipulations into a VacV clone, and select for those presenting with enhanced oncolytic properties. This work will provide a better understanding of the OV interaction with the tumour microenvironment, bringing us closer towards the development of a novel oncolytic vaccinia candidate.
Competitiondate
201712
Approvedterm2
1 yr 0 mth
Pinamesdelim
Duong, Jessie
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~